The path to understanding and overcoming advanced cancer begins with Intermountain Precision Genomics' TheraMap test, a personalized approach to cancer care.
By customizing care to patients’ DNA and matching them with targeted treatments, TheraMap can help improve results and reduce costs. This way, patients can spend less time worrying about treatment and enjoy an improved quality of life.
By streamlining the process of genomics sequencing, implementing clinical guidance, and shifting focus to targeted therapies, our advanced-stage cancer patients enjoy a better quality of life.
TheraMap simpliﬁes patient care for oncologists by providing straightforward interpretations, prioritization of therapies, and the next steps speciﬁc to each patient’s genomic results.
TheraMap Testing Options
- TheraMap: Solid Tumor
TheraMap: Solid Tumor is a hybrid capture DNA- and RNA-based test that detects SNV, INDELs, Copy Number Variants (CNV), and fusions in solid tumors. TheraMap is validated for all solid tumor types and includes sequencing over 500 genes identified as relevant to cancer treatment, relevant gene fusion events, including NTRK fusions, as well as the important microsatellite instability (MSI) and tumor mutational burden (TMB) biomarkers.
- In cases where the specimen is scant, Intermountain Precision Genomics can reflex to a smaller version of the solid tumor panel that tests fewer genes (58 total), but still detects all the NCCN-specified genes, including NTRK fusions. Providers with concerns that a specimen may be insufficient are encouraged to select TheraMap: Solid Tumor with Reflex when ordering
- TheraMap: Myeloid Malignancies utilizes DNA from whole blood or bone marrow samples to sequence 60 genes in an effort to identify pathologic variants that are common in various hematologic malignancies including acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and myelodysplastic/myeloproliferative overlap disorders.
TheraMap analyzes both DNA and RNA, detecting SNVs, INDELS, Copy Number Variants (CNV), gene fusions, and breakpoints in solid tumors. In contrast to amplicon or other targeted methods, TheraMap has a hybrid capture technology that is one of the most sensitive methodologies for detecting gene fusion events from known and novel partners.
View the gene lists here:
Our Process - TheraMap: Solid Tumor panels
- The ordering oncologist first completes the test requisition, which alerts Intermountain Precision Genomics to begin the sample acquisition process.
- Once the specimen is received, the Intermountain Precision Genomics’ CAP - and CLIA -certified laboratory utilizes state-of-the-art, next-generation sequencing, additional molecular methods, and proprietary data analytics, to identify all clinically relevant cancer mutations.
- The Molecular Tumor Board, a group of clinical experts and precision medicine key opinion leaders, then reviews TheraMap: Solid Tumor results and provides recommendations for specific therapies and treatments. If a variant in a known germline cancer-risk gene is detected, the case will be sent to the Germline Committee for review by our germline experts. Based on the patient's family history and molecular profile, the committee may recommend genetic counseling or a specific Inhera test.
- A report is sent to the ordering provider with treatment information on variants that are clinically actionable and a list of available clinical trials.
Our Process – TheraMap: Myeloid Malignancies
- TheraMap: Myeloid Malignancies is most often ordered as part of a routine bone marrow evaluation. The test may be requested with the initial requisition or added on by the reviewing pathologist or the clinician upon review of the report. (Add-on orders can be placed using a TheraMap order form, bone marrow requisition, or through iCentra.)
- It is highly recommended to only order the test with a concurrent bone marrow or peripheral blood review.
- Add-on orders require both an existing/previous pathology review (i.e. peripheral blood or bone marrow) and availability of extracted DNA from the sample.
- The completion of an add-on order alerts Intermountain Precision Genomics to begin the sample acquisition process.
- Once the specimen is received, the Intermountain Precision Genomics’ CAP- and CLIA-certified laboratory utilizes state-of-the-art, next-generation sequencing and proprietary data analytics to identify all clinically relevant variants.
- The completed report is both sent to the ordering provider and available for review on iCentra.
Three ways to order:
Please reference this document for specimen and shipping requirements.
Your TheraMap test results will come as formatted in this sample report.
TheraMap: Solid Tumor and the panel's reflex version are covered by Medicare. Additionally, many private payers offer coverage for testing late-stage cancers based on the necessity of the patient. We recommend that you work with the patient’s insurance company for any pre-authorization requirements prior to ordering. If you have any questions, or would like assistance, please reach out to our genomics navigators at (435) 251-5740 or email@example.com.
Dr. Derrick Haslem, MD, Associate Medical Director of Oncology, et al, composed a study on precision cancer medicine in patients with advanced-stage cancer, finding those who received precision medicine treatment had improved clinical outcomes without increasing healthcare costs. Download and read the publication: Haslem et al | Journal of Oncology Practice.